Analysts Set Hims & Hers Health, Inc. (NYSE:HIMS) PT at $29.37

Posted by Brian Himes on Jun 24th, 2026

Shares of Hims & Hers Health, Inc. (NYSE:HIMS – Get Free Report) have earned an average rating of “Hold” from the sixteen analysts that are presently covering the company, MarketBeat.com reports. Two equities research analysts have rated the stock with a sell rating, ten have assigned a hold rating and four have given a buy rating to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $29.3667.

Several equities research analysts have weighed in on the stock. Citigroup increased their price target on shares of Hims & Hers Health from $24.00 to $28.00 and gave the company a “neutral” rating in a research report on Tuesday, May 12th. Canaccord Genuity Group set a $32.00 target price on shares of Hims & Hers Health in a research report on Tuesday, May 12th. Weiss Ratings cut shares of Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a research report on Tuesday, May 12th. Morgan Stanley dropped their target price on shares of Hims & Hers Health from $40.00 to $21.00 and set an “equal weight” rating for the company in a research report on Tuesday, February 24th. Finally, Barclays raised their target price on shares of Hims & Hers Health from $29.00 to $39.00 and gave the stock an “overweight” rating in a research report on Wednesday, June 17th.

View Our Latest Report on HIMS

Insider Transactions at Hims & Hers Health

In other news, COO Michael Chi sold 14,027 shares of the firm’s stock in a transaction dated Wednesday, June 17th. The shares were sold at an average price of $31.50, for a total value of $441,850.50. Following the completion of the sale, the chief operating officer directly owned 432,124 shares of the company’s stock, valued at approximately $13,611,906. This trade represents a 3.14% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider Irene Becklund sold 4,490 shares of the firm’s stock in a transaction dated Wednesday, June 17th. The stock was sold at an average price of $31.50, for a total transaction of $141,435.00. Following the completion of the sale, the insider directly owned 6,790 shares of the company’s stock, valued at approximately $213,885. This represents a 39.80% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last 90 days, insiders sold 163,973 shares of company stock worth $4,859,194. 11.76% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Hims & Hers Health

Several institutional investors and hedge funds have recently modified their holdings of HIMS. Flagship Harbor Advisors LLC purchased a new position in Hims & Hers Health during the 4th quarter valued at about $28,000. Binnacle Investments Inc purchased a new position in Hims & Hers Health during the 3rd quarter valued at about $28,000. Bogart Wealth LLC lifted its position in Hims & Hers Health by 235.8% during the 4th quarter. Bogart Wealth LLC now owns 900 shares of the company’s stock valued at $29,000 after acquiring an additional 632 shares during the period. Geneos Wealth Management Inc. purchased a new position in Hims & Hers Health during the 1st quarter valued at about $30,000. Finally, Greenline Wealth Management LLC purchased a new position in Hims & Hers Health during the 4th quarter valued at about $36,000. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Price Performance

Shares of Hims & Hers Health stock opened at $33.00 on Friday. Hims & Hers Health has a 52-week low of $13.74 and a 52-week high of $70.43. The stock has a market capitalization of $7.64 billion, a price-to-earnings ratio of -366.67, a price-to-earnings-growth ratio of 47.94 and a beta of 2.37. The company has a fifty day moving average of $27.29 and a 200-day moving average of $26.51. The company has a debt-to-equity ratio of 2.18, a quick ratio of 1.56 and a current ratio of 1.69.

Hims & Hers Health (NYSE:HIMS – Get Free Report) last announced its quarterly earnings data on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.04 by ($0.44). The business had revenue of $608.10 million during the quarter, compared to analysts’ expectations of $616.84 million. Hims & Hers Health had a negative net margin of 0.56% and a positive return on equity of 6.10%. Hims & Hers Health’s revenue for the quarter was up 3.8% on a year-over-year basis. During the same period last year, the company posted $0.20 EPS. Equities research analysts expect that Hims & Hers Health will post 0.05 EPS for the current year.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

Positive Sentiment: Hims & Hers is expanding its GLP-1 weight-loss offering through a partnership with Novo Nordisk, which could broaden access to popular drugs like Wegovy and Ozempic and support revenue growth. Hims & Hers Health (HIMS) Expands GLP 1 Offerings With Novo Nordisk Deal And Eucalyptus Buy
Positive Sentiment: The company also announced a new chief medical officer, Dr. Anant Vinjamoori, which may be viewed as a strengthening of its leadership team. Telehealth platform names Dr. Anant Vinjamoori as Hims CMO
Neutral Sentiment: Analyst commentary and market articles highlighted Hims & Hers as one of several stocks that may deserve another look, but also noted that bearish price targets signal ongoing skepticism. 2 Unpopular Stocks That Deserve a Second Chance and 1 We Question
Negative Sentiment: Insiders continued to trim holdings, with CFO Oluyemi Okupe and insider Patrick Harrison Carroll both selling shares under pre-arranged 10b5-1 plans, which can still weigh on investor sentiment. CFO insider sale filing
Negative Sentiment: The stock also recently fell more than the broader market, reinforcing concerns that some traders may be taking profits after the recent rally. Hims & Hers Health, Inc. (HIMS) Sees a More Significant Dip Than Broader Market: Some Facts to Know

About Hims & Hers Health

(Get Free Report)

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.